Key statistics
As of last trade Innoviva Inc (HVE:DUS) traded at 18.90, -1.56% below its 52-week high of 19.20, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 18.90 |
|---|---|
| High | 18.90 |
| Low | 18.90 |
| Bid | 18.90 |
| Offer | 19.40 |
| Previous close | 18.80 |
| Average volume | 34.29 |
|---|---|
| Shares outstanding | 74.77m |
| Free float | 74.01m |
| P/E (TTM) | 17.59 |
| Market cap | 1.70bn USD |
| EPS (TTM) | 1.29 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 11:31 GMT.
More ▼
Press releases
- U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
- Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
- Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
